EUVIMEDEUVIMED entdecken
Crossref

Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival

Lara Schwieger, Lauren M Postlewait, Yi Liu, Stephanie Jou, Sha Yi, Limin Peng, Xiaoxian Li

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07368-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Lara Schwieger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, Grady Memorial Hospital, Emory University, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Receptors, Estrogen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: In metastatic breast cancer, differences in expression patterns of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) between the primary tumor (PT) and metastatic site (MET) have been reported. However, there is limited understanding of the relationship of tumor subtype discordance and overall survival (OS). We evaluated patterns of ER/PR/HER2 in PTs and corresponding METs and assessed the relationship between these patterns and OS. METHODS: Patients diagnosed at our center with metastatic breast cancer (2011-2020) were included. ER/PR were stratified as 10% by immunohistochemistry and HER2 as positive/negative by immunohistochemistry/FISH. Tumor subtypes were classified as ER or PR + /HER2-, HER2+ , or triple-negative. Biomarker discordance data from PTs to METs were analyzed for expression patterns. OS was assessed. RESULTS: Of 254 patients, 41 (16.1%) had synchronous and 213 (83.9%) had metachronous METs. Category change of ER/PR/HER2 expression was observed in 56 (22.0%), 117 (40.5%), and 30 (11.8%) patients, respectively. Tumor subtype changed in 56 (22.0%) patients. We identified a difference between PT and MET from ER > 10% to ER 10% to PR 10% to PR 1-10% (n = 18,16.1%, p 0.05). CONCLUSION: Tumor expression of ER/PR/HER2 can differ between the PT and MET. Loss of ER/PR expression is common and may be related to worse survival. Routine assessment of MET tumor markers could inform prognosis and therapeutic decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneHumansFemaleMiddle AgedAgedAdultPrognosisNeoplasm MetastasisImmunohistochemistryAged, 80 and over

Stichwörter der Autor:innen

Breast cancerBreast pathologyHormone receptorsMetastasesTumor markers

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • Division of Surgical Oncology, Department of Surgery, Grady Memorial Hospital, Emory University, Atlanta, GA, USA.
  • Division of Surgical Oncology, Department of Surgery, Grady Memorial Hospital, Emory University, Atlanta, GA, USA. lauren.postlewait@emory.edu.
  • Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
  • Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
  • Department of Pathology and Laboratory Medicine, East Carolina University, Greenville, NC, USA.
  • Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA. xli40@emory.edu.

Zitieren

APA

Schwieger, L., Postlewait, L. M., Liu, Y., Jou, S., Yi, S., Peng, L., & Li, X. (2024). Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07368-w

Vancouver

Schwieger L, Postlewait LM, Liu Y, Jou S, Yi S, Peng L, et al. Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07368-w

BibTeX
@article{Schwieger2024,
  author = {Schwieger, Lara and Postlewait, Lauren M and Liu, Yi and Jou, Stephanie and Yi, Sha and Peng, Limin and Li, Xiaoxian},
  title = {Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07368-w}
}
Kostenlos starten →